CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Low dose naltrexone +1 moredrug
Likely dose
Low dose naltrexone 4.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03278886
NCT03278886Phase 2Completed
CompareCT.gov

Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems

Boston Medical Center·interventional·Posted Sep 12, 2017·Updated Aug 24, 2020

In Brief

A Phase 2 clinical trial evaluating Low dose naltrexone and Nalmefene for HIV Infection and 2 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study is a randomized controlled trial (RCT) to assess the feasibility, tolerability, and safety of using opioid receptor antagonists (naltrexone and nalmefene) to treat pain among HIV-infected persons with heavy alcohol use and chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection, Alcohol Use, Pain
CountriesRussia
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 12, 2017
Enrollment StartJul 3, 2018
Primary CompletionDec 19, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.8 years ago

Interventions

Low dose naltrexonedrug

4.5 mg of low dose naltrexone taken once daily for 8 weeks

Nalmefenedrug

18 mg of nalmefene taken once daily for 8 weeks